keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine, liver

keyword
https://www.readbyqxmd.com/read/28229838/-treatment-of-gastroenteropancreatic-neuroendocrine-tumors-with-177lu-dota-tate-experience-of-the-portuguese-institute-of-oncology-in-porto
#1
Inês Lucena Sampaio, Henrique Vara Luiz, Liliana Sobral Violante, Ana Paula Santos, Luís Antunes, Isabel Torres, Cristina Sanches, Isabel Azevedo, Hugo Duarte
INTRODUCTION: The purpose of this article is to report the experience of the Portuguese Institute of Oncology - Porto in the treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE, regarding the safety and efficacy of this treatment modality. MATERIAL AND METHODS: A retrospective analysis of clinical reports of patients with gastroenteropancreatic neuroendocrine tumors undergoing treatment with 177Lu-DOTA-TATE between April 2011 and November 2013 was performed...
November 2016: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28225311/prognostic-factors-for-survival-of-men1-patients-with-duodenopancreatic-tumors-metastatic-to-the-liver-results-from-the-dmsg-study-group
#2
Elfi B Conemans, Sjoerd Nell, Carolina R C Pieterman, Wouter W de Herder, Olaf M Dekkers, Ad R Hermus, Anouk N van der Horst-Schrivers, Peter H Bisschop, Bas Havekes, Madeleine L Drent, Menno R Vriens, Gerlof D Valk
Objective Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a majority of patients with Multiple Endocrine Neoplasia Type 1 (MEN1) and are the leading cause of death. Overall survival (OS) and prognostic factors for patients with liver metastases from DP-NETs are not known. Design and Methods Cohort study using the Dutch National MEN1 database, which includes >90% of the Dutch MEN1 population between 1990-2014. OS was assessed with time to event analysis, and prognostic factors were evaluated...
February 22, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28213807/in-liver-metastases-from-small-intestinal-neuroendocrine-tumors-sstr2a-expression-is-heterogeneous
#3
Mongkon Charoenpitakchai, Eric Liu, Zhiguo Zhao, Tatsuki Koyama, Won Jae Huh, Jordan Berlin, Kenneth Hande, Ronald Walker, Chanjuan Shi
We examined somatostatin receptor type 2A (SSTR2A) expression in primary and metastatic small intestinal neuroendocrine tumors (SI-NETs). We retrieved 156 liver metastases from 26 patients (10 males, 16 females) who had two or more liver lesions resected. A representative formalin-fixed paraffin-embedded section of tumor tissue from each liver metastasis and from the primary tumor, when available, were immunohistochemically stained for SSTR2A. SSTR2A expression was evaluated by the Her2/neu-scoring system and the scoring system proposed by Volante et al...
February 17, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28210802/poorly-differentiated-colorectal-neuroendocrine-tumour-ct-differentiation-from-well-differentiated-neuroendocrine-tumour-and-poorly-differentiated-adenocarcinomas
#4
Ji Hee Kang, Se Hyung Kim, Joon Koo Han
OBJECTIVE: The differentiation of poorly-differentiated neuroendocrine tumours (PD-NETs), well-differentiated NETs (WD-NETs), and adenocarcinomas (ADCs) is important due to different management options and prognoses. This study is to find the differential CT features of colorectal PD-NETs from WD-NETs and ADCs. MATERIALS AND METHODS: CT features of 25 colorectal WD-NETs, 36 PD-NETs, and 36 ADCs were retrospectively reviewed. Significant variables were assessed using univariate and multivariate analyses...
February 16, 2017: European Radiology
https://www.readbyqxmd.com/read/28210088/clinicopathological-treatment-and-prognosis-study-of-43-gastric-neuroendocrine-carcinomas
#5
De-Jun Liu, Xue-Liang Fu, Wei Liu, Lu-Ying Zheng, Jun-Feng Zhang, Yan-Miao Huo, Jiao Li, Rong Hua, Qiang Liu, Yong-Wei Sun
AIM: To provide more information and therapeutic methods about gastric neuroendocrine carcinomas (G-NECs) which occur rarely but are highly malignant and clinically challenging. METHODS: We retrospectively analyzed the clinicopathological characteristics, treatments, and prognosis of 43 G-NEC patients at our hospital between January 2007 and December 2014. The diagnosis was based on the 2010 World Health Organization criteria. RESULTS: Forty-three G-NECs containing 39 small cell carcinomas and 4 large cell NECs with Ki67 > 60% were included in this study, accounting for only 0...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28206942/mixed-hepatocellular-carcinoma-neuroendocrine-carcinoma-of-the-liver
#6
Erin Baker, Carl Jacobs, John Martinie, David A Iannitti, Dionisios Vrochides, Ryan Z Swan
We present the case of a 76-year-old male found to have a large tumor involving the left lateral lobe of the liver, presumed to be hepatocellular carcinoma (HCC). After resection, pathologic features demonstrated both high-grade HCC and high-grade neuroendocrine carcinoma (NEC). Areas of NEC stained strongly for synaptophysin, which was not present in HCC component. The HCC component stained strongly for Hep-Par 1, which was not present in the NEC component. The patient underwent genetic analysis for biomarkers common to both tumor cell types...
November 1, 2016: American Surgeon
https://www.readbyqxmd.com/read/28203303/refractory-carcinoid-syndrome-a-review-of-treatment-options
#7
REVIEW
Rachel P Riechelmann, Allan A Pereira, Juliana F M Rego, Frederico P Costa
Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs (SSAs) being the first-line option for symptom management. However, symptomatic progression eventually occurs and in this scenario of a refractory CSy; several treatment options have been studied such as dose escalation of SSA, interferon and liver-directed therapies. Nevertheless, recent phase III trials have contributed to the understanding and management of this condition...
February 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#8
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28196718/the-neuropeptide-galanin-is-up-regulated-during-cholestasis-and-contributes-to-cholangiocyte-proliferation
#9
Matthew McMillin, Gabriel Frampton, Stephanie Grant, Sharon DeMorrow
During the course of cholestatic liver diseases, mitotically dormant cholangiocytes proliferate and subsequently acquire a neuroendocrine phenotype. Galanin is a neuroendocrine factor responsible for regulation of physiological responses, such as feeding behavior and mood, and has been implicated in the development of fatty liver disease, although its role in biliary hyperplasia is unknown. Biliary hyperplasia was induced in rats via bile duct ligation (BDL) surgery, and galanin was increased in serum and liver homogenates from BDL rats...
February 11, 2017: American Journal of Pathology
https://www.readbyqxmd.com/read/28193572/systematic-review-of-early-and-long-term-outcome-of-liver-resection-for-metastatic-breast-cancer-is-there-a-survival-benefit
#10
REVIEW
Tae Gon Yoo, Isaac Cranshaw, Reuben Broom, Sanjay Pandanaboyana, Adam Bartlett
BACKGROUND: Isolated liver metastases occur rarely in patients with metastatic breast cancer. The success of liver resection (LR) for other metastatic disease has led centres to explore the option of LR for patients with isolated breast cancer liver metastases (BCLM). A number of small series have been published in the literature, however the evidence is conflicting. This study aimed to systematically review the literature to determine the perioperative outcome and survival of patients undergoing LR for BCLM...
February 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28179411/pancreatic-neuroendocrine-tumors-and-emt-behavior-are-driven-by-the-csc-marker-dclk1
#11
Yu Ikezono, Jun Akiba, Mitsuhiko Abe, Takafumi Yoshida, Fumitaka Wada, Toru Nakamura, Hideki Iwamoto, Atsutaka Masuda, Takahiko Sakaue, Hirohisa Yano, Takuji Torimura, Osamu Tsuruta, Hironori Koga
: Doublecortin-like kinase 1 (DCLK1), a marker for intestinal and pancreatic cancer stem cells, is highly expressed in neuroblastomas. This study was conducted to assess DCLK1 expression levels in pancreatic neuroendocrine tumor (PNET) tissues and to explore the roles of this molecule in clinical tissue from multiple PNET patients, cells (BON1, QGP1, and CM), and tumor xenografts. Immunohistochemically, all PNET tissues highly and diffusely expressed DCLK1 as a full-length isoform, identical to that detected in primary liver NETs...
February 8, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28178157/the-prognostic-influence-of-the-proliferative-discordance-in-metastatic-pancreatic-neuroendocrine-carcinoma-revealed-by-peptide-receptor-radionuclide-therapy-case-report-and-review-of-literature
#12
Nathanaëlle Montanier, Juliette Joubert-Zakeyh, Caroline Pétorin, Pierre François Montoriol, Salwan Maqdasy, Antony Kelly
RATIONALE: Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the management of grade 3 (G3) unresectable pancreatic neuroendocrine carcinoma (pNEC). To date, no study has evaluated the efficacy of PRRT in such tumors...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28163289/a-case-of-metachronous-liver-metastasis-from-neuroendocrine-carcinoma-of-the-stomach-at-1-year-and-10-months-after-endoscopic-submucosal-dissection
#13
Masafumi Hashiguchi, Tsutomu Tamai, Yuuichiro Nasu, Fumisato Sasaki, Michiyo Higashi, Kaoru Hijikuro, Hisatomo Futawatari, Kouichirou Shigeta, Susumu Hasegawa, Akio Ido
A 77-year-old man underwent endoscopic submucosal dissection (ESD) of a type 0-IIc tumor located in the cardiac part of the stomach. The pathological diagnosis of the tumor was poorly differentiated tubular adenocarcinoma with submucosal invasion depth;therefore, radical gastrectomy was also performed. After 1 year and 10 months, liver metastasis was detected because of which partial liver resection was performed. The pathological diagnosis of the tumor was neuroendocrine carcinoma (NEC). The pathology of the ESD specimen was re-examined, and a diagnosis of gastric NEC was made;furthermore, the liver tumor was regarded as metachronous metastasis...
2017: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/28160741/report-of-two-cases-of-large-cell-neuroendocrine-carcinoma-of-duodenal-ampulla-with-contrasting-outcomes-following-pancreaticoduodenectomy-according-to-the-use-of-adjuvant-chemotherapy
#14
Naoya Imamura, Atsushi Nanashima, Masahide Hiyoshi, Yoshiro Fujii
INTRODUCTION: Large-cell neuroendocrine carcinoma (LCNEC) in the duodenal ampulla of Vater is a rare malignant tumor, with frequent postoperative recurrence and poor prognosis even following complete resection. Effective adjuvant chemotherapy is expected to offer longer survival. PRESENTATION OF CASE: We present two patients with LCNEC accompanied by components of tubular adenocarcinoma/adenoma in the duodenal ampulla of Vater who underwent pancreaticoduodenectomy (PD), resulting in longer survival of 1 patient...
January 17, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28146608/neuroendocrine-liver-metastasis-the-chance-to-be-cured-after-liver-surgery
#15
Fabio Bagante, Gaya Spolverato, Katiuscha Merath, Lauren McLendon Postlewait, George A Poultsides, Matthew G Mullen, Todd W Bauer, Ryan C Fields, Jorge Lamelas, Hugo P Marques, Luca Aldrighetti, Thuy Tran, Shishir K Maithel, Timothy M Pawlik
BACKGROUND AND OBJECTIVE: Neuroendocrine liver metastasis tumors (NELM) are a heterogeneous group of neoplasms with varied histologic features and a wide range of clinical behaviors. We aimed to identify the fraction of patients cured after liver surgery for NELM. METHODS: Cure fraction models were used to analyze 376 patients who underwent hepatectomy with curative intent for NELM. RESULTS: The median and 5-year disease-free survival (DFS) were 4...
February 1, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28144395/new-therapeutic-approaches-to-metastatic-gastroenteropancreatic-neuroendocrine-tumors-a-glimpse-into-the-future
#16
REVIEW
Esther Una Cidon
Neuroendocrine (NE) gastroenteropancreatic tumors are a heterogeneous group of neoplasias arising from neuroendocrine cells of the embryological gut. Their incidence have increased significantly over the past 3 decades probably due to the improvements in imaging and diagnosis. The recent advances in molecular biology have translated into an expansion of therapeutic approaches to these patients. Somatostatin analogs, which initially were approved for control of hormonal syndromes, have recently been proven to inhibit tumor growth...
January 15, 2017: World Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28138732/limited-value-of-ga-68-dotatoc-pet-ct-in-routine-screening-of-patients-with-multiple-endocrine-neoplasia-type-1
#17
Max B Albers, Damiano Librizzi, Caroline L Lopez, Jerena Manoharan, Jonas C Apitzsch, Emily P Slater, Carmen Bollmann, Peter H Kann, Detlef K Bartsch
BACKGROUND: Routine screening is recommended for patients with multiple endocrine neoplasia type 1 (MEN1) to enable early detection and treatment of associated neuroendocrine neoplasms (NEN). Gallium(68)-DOTATOC-Positron emission tomography combined with computed tomography (Ga-68-DOTATOC-PET-CT) is a very sensitive and specific imaging technique for the detection of sporadic neuroendocrine tumors. The present study evaluated the value of Ga-68-DOTATOC-PET-CT in routine screening of patients with MEN1...
January 30, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28138688/twins-in-spirit-part-iv-177-lu-%C3%A2-high%C3%A2-affinity-dotatate-a-promising-new-tracer-for-peptide-receptor-radiotherapy
#18
Claudia Brogsitter, Holger Hartmann, Gerd Wunderlich, Margret Schottelius, Hans-Jürgen Wester, Jörg Kotzerke
AIM: Besides the use of somatostatin analogues, small molecules like sunitinib and everolimus as well as conventional chemotherapy, peptide receptor radiotherapy (PRRT) using radiolabelled somatostatin analogues has gained an important role in the treatment of inoperable, metastasized neuroendocrine tumours (NET). There are various radiotracers in use. Based on our experience with the PET tracer [(68)Ga]DOTA-3-iodo-Tyr(3)-octreotate ([(68)Ga]HA-DOTATATE), a DOTATATE derivative with an increased binding affinity to hsst5, the current retrospective analysis is exploring the therapeutic potential of [(177)Lu]HA-DOTATATE...
January 31, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28133140/-multiple-metachronal-liver-metastases-from-a-rectal-neuroendocrine-tumor-controlled-by-repeated-transcatheter-arterial-chemoembolization
#19
Yoshihiro Morimoto, Yoshinori Kagawa, Atsushi Naito, Takeshi Kato, Yasuo Oneda, Tomo Ishida, Yasufumi Sato, Ryuichi Kuwahara, Kohei Murakami, Yoshiteru Katsura, Yoshiaki Ohmura, Atsushi Takeno, Yutaka Takeda, Shigeyuki Tamura
A 60-year-old woman was diagnosed with a rectal neuroendocrine tumor(NET)with SM invasion.We performed laparoscopic low anterior resection with D3 lymph node dissection.Pathological findings were rectal NET, G1, pSM(9,000 mm), ly0, v0, pN0, PM0, DM0, pR0, pStage I .Four years and 6 months later, contrast enhanced abdominal computed tomography (CECT)and contrast enhanced magnetic resonance imaging revealed multiple liver metastases.The tumors were unresectable because they were bilobar; therefore, we performed transcatheter arterial chemoembolizaion(TACE)...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133133/-a-rare-complication-of-transcatheter-arterial-injection-for-multiple-liver-metastases-of-rectal-neuroendocrine-tumor-a-case-report
#20
Kensuke Suzuki, Nozomu Sakai, Hiroaki Shimizu, Masayuki Ohtsuka, Hideyuki Yoshitomi, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Shigetsugu Takano, Daisuke Suzuki, Shingo Kagawa, Hiroyuki Nojima, Masaru Miyazaki
A 50-year-old man was diagnosed with multiple bilobar liver metastases of rectal neuroendocrine tumor(NET). Although he received octreotide for 6 months and everolimus for 10 months, the liver metastases gradually increased in size. Therefore, we decided to perform transcatheter arterial infusion(TAI)with miriplatin. The serum total bilirubin level increased to 13.1 mg/dL 9 days after treatment, and it took 2 months to return to the normal range. CT scan demonstrated that most of the liver tumors had remarkably shrunk 4 months after treatment, and the patient has no sign of tumor regrowth even 12 months after treatment...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
77982
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"